Chemotherapy + immunotherapy + anti-vascular therapy and firmonertinib + capmatinib prolong OS in EGFR-mutated and MET amplification following disease progression on osimertinib plus savolitinib: A case report of NSCLC

Abstract

Backgound: The combination of osimertinib and savolitinib as second-line treatment after epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) resistance can significantly improve median progression-free survival (mPFS), objective response rate (ORR), and duration of remission (DOR). The combination therapy is safe and controllable, with no new safety signals or unexpected toxicity. However, the mechanism of drug resistance for tumor progression after dual-targeted therapy is currently unclear, and there is no clinical data reference for treatment after drug resistance. This case suggests some treatment options for lung adenocarcinoma patient after dual-targeted therapy with osimertinib and savolitinib.

Case presentation: A patient with EGFR-mutated lung adenocarcinoma developed mesenchymal-epithelial transition factor (MET) amplification-related resistance after first-line almonertinib. Subsequent sequential regimens—osimertinib plus savolitinib, chemo-immuno-antiangiogenesis therapy, and finally furmonertinib plus capmatini—each yielded transient benefit.

Results: The report shows that the combination of chemotherapy and immunotherapy, as well as the dual-targeted therapy of firmonertinib and capmatinib, prolonged the overall survival of the patient.

Conclusions: This case suggests some treatment options for lung adenocarcinoma patient after dual-targeted therapy with osimertinib and savolitinib. The results indicated that traditional treatment or the combination of MET-TKI with another targeted therapy may improve the prognosis of patients.

Keywords

non-small cell lung cancer / osimertinib / savolitinib / MET amplification / EGFR mutation

References

[1] Hartmaier RJ , Markovets AA , Ahn MJ , et al. Osimertinib + savolitinib to overcome acquired MET-mediated resistance in epidermal growth factor receptor-mutated, MET-amplified non-small cell lung cancer: TATTON. Cancer Discov. 2023; 13 (1): 98- 113.

[2] de Marinis F , Kim TM , Bonanno L , et al. Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study. Ann Oncol. 2025; 36 (8): 920- 933.

[3] Gourd K . 2025 ASCO annual meeting. Lancet Oncol. 2025; 26 (7): 841.

[4] Fu K , Xie F , Wang F , Fu L . Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J Hematol Oncol. 2022; 15 (1): 173.

[5] Pasquini G , Giaccone G . C-MET inhibitors for advanced non-small cell lung cancer. Expert Opin Invest Drugs. 2018; 27 (4): 363- 375.

[6] Xu L , Qi Q , Zhang Y , Cui J , Liu R , Li Y . Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: a randomized controlled study. Lung Cancer. 2019; 133: 23- 31.

[7] Wu Q , Luo W , Li W , Wang T , Huang L , Xu F . First-generation EGFR-TKI plus chemotherapy versus EGFR-TKI alone as first-line treatment in advanced NSCLC with EGFR activating mutation: a systematic review and meta-analysis of randomized controlled trials. Front Oncol. 2021; 11: 598265.

[8] Wang Q , Gao W , Gao F , et al. Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting. BMC Cancer. 2021; 21 (1): 602.

[9] Chang Q , Xu J , Qiang H , et al. EGFR tyrosine kinase inhibitor (TKI) combined with concurrent or sequential chemotherapy for patients with advanced lung cancer and gradual progression after first-line EGFR-TKI therapy: a randomized controlled study. Clin Lung Cancer. 2021; 22 (3): e395- e404.

[10] Yang Z , Chen Y , Wang Y , et al. Efficacy of EGFR-TKI plus chemotherapy or monotherapy as first-line treatment for advanced EGFR-mutant lung adenocarcinoma patients with co-mutations. Front Oncol. 2021; 11: 681429.

[11] Fang X , Xiang Y , Lu K . Almonertinib plus chemotherapy versus almonertinib alone in second-line treatment of advanced non-small cell lung cancer with mutated epidermal growth factor receptor: a retrospective study. Front Oncol. 2023; 13: 1248690.

[12] Bahcall M , Sim T , Paweletz CP , et al. Acquired MET D1228V mutation and resistance to MET inhibition in lung cancer. Cancer Discov. 2016; 6 (12): 1334- 1341.

[13] Heist RS , Sequist LV , Borger D , et al. Acquired resistance to crizotinib in NSCLC with MET exon 14 skipping. J Thorac Oncol. 2016; 11 (8): 1242- 1245.

[14] Recondo G , Bahcall M , Spurr LF , et al. Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14-mutant NSCLC. Clin Cancer Res. 2020; 26 (11): 2615- 2625.

[15] Cheng Y , Zhang T , Xu Q . Therapeutic advances in non-small cell lung cancer: focus on clinical development of targeted therapy and immunotherapy. MedComm. 2021; 2 (4): 692- 729.

[16] Liu GH , Chen T , Zhang X , Ma XL , Shi HS . Small molecule inhibitors targeting the cancers. MedComm. 2022; 3: e181.

[17] Mitsudomi T , Morita S , Yatabe Y , et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010; 11 (2): 121- 128.

[18] Cheng Y , Mok TS , Zhou X , et al. Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: results from a randomized, open-label, phase 3 trial (ARCHER 1050). Lung Cancer. 2021; 154: 176- 185.

[19] Park K , Tan EH , O'Byrne K , et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016; 17 (5): 577- 589.

[20] Westover D , Zugazagoitia J , Cho BC , Lovly CM , Paz-Ares L . Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018; 29 (suppl 1): i10- i19.

[21] Huang YH , Tseng JS , Hsu KH , et al. The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M. Sci Rep. 2021; 11: 12084.

[22] Wu SG , Liu YN , Tsai MF , et al. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. Oncotarget. 2016; 7 (11): 12404- 12413.

[23] Sos ML , Rode HB , Heynck S , et al. Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Res. 2010; 70 (3): 868- 874.

[24] Ettinger DS , Wood DE , Aisner DL , et al. Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2022; 20 (5): 497- 530.

[25] Girard N . New strategies and novel combinations in EGFR TKI-resistant non-small cell lung cancer. Curr Treat Options Oncol. 2022; 23 (11): 1626- 1644.

[26] Soria JC , Ohe Y , Vansteenkiste J , et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018; 378 (2): 113- 125.

[27] Roper N , Brown AL , Wei JS , et al. Clonal evolution and heterogeneity of osimertinib-acquired resistance mechanisms in EGFR mutant lung cancer. Cell Rep Med. 2020; 1 (1): 100007.

[28] Sidaway P . From AACR 2022. Nat Rev Clin Oncol. 2022; 19 (6): 359.

[29] Sequist LV , Han JY , Ahn MJ , et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020; 21 (3): 373- 386.

[30] Matikas A , Mistriotis D , Georgoulias V , Kotsakis A . Current and future approaches in the management of non-small-cell lung cancer patients with resistance to EGFR TKIs. Clin Lung Cancer. 2015; 16 (4): 252- 261.

[31] Hu D , Hu Y , Lei S , Wu D , Wang Y . MET tyrosine kinase inhibitors in combination with EGFR tyrosine kinase inhibitors in NSCLC patients with EGFR mutations and acquired MET alterations: a systematic review and meta-analysis. BMC Cancer. 2025; 25: 732.

[32] Liam CK , Ahmad AR , Hsia TC , et al. Randomized trial of tepotinib plus gefitinib versus chemotherapy in EGFR-mutant NSCLC with EGFR inhibitor resistance due to MET amplification: INSIGHT final analysis. Clin Cancer Res. 2023; 29 (10): 1879- 1886.

RIGHTS & PERMISSIONS

The Author(s). Malignancy Spectrum published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.